医学
PCSK9
内膜增生
阿利罗库单抗
支架
再狭窄
经皮冠状动脉介入治疗
内科学
内分泌学
低密度脂蛋白受体
心肌梗塞
胆固醇
载脂蛋白B
脂蛋白
载脂蛋白A1
平滑肌
作者
Yustina M. Puspitasari,Stefano Ministrini,Luca Liberale,Ana Vukolic,Philine Baumann-Zumstein,Erik W. Holy,Fabrizio Montecucco,Thomas F. Lüscher,Giovanni G. Camici
标识
DOI:10.1016/j.vph.2023.107170
摘要
Despite advances in pharmacotherapy and device innovation, in-stent restenosis (ISR) and stent thrombosis (ST) remain serious complications following percutaneous coronary intervention (PCI) procedure with stent implantation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in plasma cholesterol homeostasis and recently emerged as a therapeutic target for hypercholesterolemia. Antibody-based PCSK9 inhibition is increasingly used in different subsets of patients, including those undergoing PCI. However, whether PCSK9 inhibition affects outcome after stent implantation remains unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI